Quercetin suppresses cell viability in triple-negative breast cancer by targeting ORM2

Xianhua Liu1, Zhijun Chen2

  • 1Department of Pathology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University Fuzhou 350001, Fujian, China.

PubMed

Insights

Quercetin (QUE) inhibits triple-negative breast cancer (TNBC) cell viability by interacting with ORM2. This study highlights ORM2 as a potential therapeutic target for aggressive TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options.
  • Quercetin (QUE) exhibits potential anti-cancer properties.
  • The role of ORM2 in TNBC progression and its interaction with QUE requires further investigation.

Purpose of the Study:

  • To investigate the anti-cancer effects of Quercetin (QUE) on triple-negative breast cancer (TNBC) cells.
  • To determine the role of ORM2 in TNBC and its interaction with QUE.
  • To evaluate QUE as a potential therapeutic agent for TNBC.

Main Methods:

  • Cell viability assays (IC50 determination) in TNBC, non-TNBC, and normal breast cell lines.
  • Quantitative analysis of ORM2 expression in clinical samples and cell lines.
  • In vivo studies using an orthotopic mice model.
  • Molecular docking and protein-protein interaction network analysis.

Main Results:

  • QUE inhibited cell viability in both TNBC and non-TNBC cell lines.
  • ORM2 expression was higher in TNBC cells and tissues compared to normal controls.
  • Knockdown of ORM2 reduced TNBC cell viability.
  • QUE treatment downregulated ORM2 expression and decreased TNBC cell viability in vitro and in vivo.
  • Molecular docking suggested direct binding of QUE to ORM2.

Conclusions:

  • Quercetin (QUE) exhibits direct anti-cancer effects on triple-negative breast cancer (TNBC) by inhibiting cell viability.
  • The interaction between QUE and ORM2 is a key mechanism underlying QUE's efficacy in TNBC.
  • ORM2 represents a promising therapeutic target for TNBC treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K